Psoriasis

A study recently explored the differences in baseline characteristics between responders to anti-tumor necrosis factor (anti-TNF) therapy and insufficient responders with moderate-to-severe psoriasis. Read what researchers discovered in this article.

Interleukin-29 (IL-29) is a newly discovered cytokine that has become the subject of increased research attention for its role in inflammation and inflammatory autoimmune disorders and therefore as a target for novel therapeutic development.

With 4 decades of dermatology advances, we asked the very dermatologist experts who we often contact to help us to report on the milestones to weigh in on what they think have made the most difference in theirs and their patients’ lives.

Over the past 40 years, there have been major dermatological breakthroughs that have changed the way doctors treat patients, along with the very treatments they use. 

It is well established that psoriasis is associated with cardiometabolic disease, though the reason why remains unclear. This study followed pregnant women and mothers with psoriasis over an 11 year period to gain insight into the link between the immune-mediated skin disease and cardiometabolic disease.

Pruritus frequently afflicts psoriasis patients, but few studies explore the role of pruritus in regards to disease activity, pharmacotherapy or demographics. This study attempts to fill that gap.

Weight-based dosing of apremilast appeared to ensure comparable efficacy, safety and tolerability with in kids as in adults, and should be explored in future studies.

Psoriasis and atopic dermatitis patients want more nonsteroidal topical options. This expert breaks down newly available treatments and those to come.

Psoriasis has been strongly linked to metabolic and Type 2 diabetes, but the exact relationship between psoriasis and Type 2 diabetes remains ambiguous. This study aimed to fill that gap.

This slideshow breaks down important considerations to keep in mind when evaluating psoriasis patient for psoriatic arthritis.

A recent study discovered that body mass index (BMI) and age of disease onset may play a part in the development of hypertension in psoriatic arthritis and psoriasis. Read what researchers found in this article.

The realization of the critical importance of the IL-17 and 23 pathways have led to the development of numerous therapies that target parts of the immune system.

Researchers in Taiwan investigated whether behavioral modifications such as weight reduction, alcohol abstinence, smoking cessation and exercise could impact psoriasis severity. Read what they discovered in this article.

Researchers employed the the Citizen Pscientist, an online patient portal developed by the National Psoriasis Foundation, to investigate chronic sleep dysfunction prevalence in psoriasis. Read what they discovered in this article. 

In this table, we highlight how psoriasis treatments have evolved over the past four decades. 

New psoriasis treatments are making their way to market. This supplement and the corresponding August issue take a broad look at the evolving understanding of the pathogenesis of psoriasis, the expanding treatment armamentarium, co-morbidity considerations, and financial considerations of new technologies. 

Psoriasis patients face a long list of comorbidities, increased medical costs and increased mortality. Experts agree that the burden of psoriasis is heavy - what can dermatologists do to offer relief?

Psoriasis does not appear to impact fertility, but there are conflicting data on whether psoriasis itself affects the risk of pregnancy complications in women of childbearing age. This expert weighs in on the subject.

About one-third of patients with psoriasis are children or adolescents. Still, little research exists on treating this patient population. New disease management guidelines and emerging studies seek to fill the gap.

Treatment recommendations for psoriasis patients with specific comorbidities.

Based on current data, biosimilars are therapeutically equivalent to their progenitors, says these experts.

“The landscape of biologics and biosimilars is changing rapidly, and for the better,” says Mark Lebwohl, M.D. Biologics have given patients the possibility of complete psoriasis clearance and control of their psoriatic arthritis (PsA), which were not options 20 years ago, adds Alice Gottlieb, M.D., Ph.D.

With the high incidence of psoriasis and psoriatic arthritis among patients who are obese, it’s important for dermatologists to address weight and weight management. But, having that conversation is not always easy. Dr. Soltani-Arabshahi offers tips to help you talk to your psoriasis patients about their weight.

Data shows obesity is prevalent among patients with psoriasis and psoriatic arthritis, but the exact role weight plays in contributing to psoriatic disease and its severity is still unknown. At a minimum, industry experts agree that addressing obesity can be vital in treating psoriatic disease.

Patients often don’t talk about the impact of genital psoriasis because of the stigmatization, feeling shy or fear of judgement. It's up to dermatologists to proactively ask patients about their symptoms, urges a recent review.

Test your knowledge by answering these five questions about different psoriasis cases.

Ortho Dermatologics announced that halobetasol propionate and tazarotene lotion, 0.01%/0.045% (Duobrii, Ortho Dermatologics) is now commercially available to healthcare providers, according to a press release issued June 25.

A recent study found that Psoriasis Epidemiology Screening Tool (PEST) may help dermatologists identify which patients need a rheumatology referral. 

A recent study explored why black individuals with psoriasis are disproportionately under treated. Authors compared differences in the perceptions and understanding of psoriasis therapies in both black and Caucasian patients. Here’s what they found.